NCI-2017-02047

MA.39 Tailor RT A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

This is a research study to see if some women with breast cancer can skip a type of radiation treatment (regional radiotherapy) without affecting their chances of recovery. The goal is to avoid unnecessary side effects from radiation treatment for some women who may not need it. Women with Early-stage breast cancer that has spread to nearby lymph nodes (low-risk) and have Hormone receptor-positive (ER+) breast cancer, HER2-negative (HER2-) are eligible to participate in this study.

HER-2 negative: It is a type of breast cancer where cancer cells have normal levels of the protein called HER-2. Cancer cells that are HER-2 negative grow more slowly and are less likely come back or spread to other parts of the body than cancers that have too much HER-2.

Hormone Receptor positive: It is a type of breast cancer where the cancer cells have receptors on their surface that can attach to hormones in the body, particularly estrogen and/or progesterone. When these receptors attach to hormones, they can stimulate the cancer cells to grow.

Regional radiotherapy: Radiotherapy to the whole breast/chest area and the surrounding lymph glands is called regional radiotherapy.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT03488693

NCI-2022-08654

Clinical Trial Site: Einstein/Columbia

To see all available clinical trials click here.